Conformational dynamics of insulin

Frontiers in Endocrinology

Volumn 2, Issue OCT, 2011, Pages

  Hua, Qing Xin ^a   Jia, Wenhua ^a   Weiss, Michael A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amide proton exchange; Diabetes mellitus; Hydrogen bond; NMR spectroscopy; Protein Dynamics; Protein Engineering; Protein structure; Protein Therapeutics

Indexed keywords

EID: 84874384424     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2011.00048     Document Type: Article

References (91)

1. Antolíková, E., Žáková, L., Turken-burg, J. P., Watson, C. J., Hančlová, I., Šanda, M., Cooper, A., Kraus, T., Brzozowski, A. M., and Jiráček, J. (2011). Non-equivalent role of inter-and intra-molecular hydrogen bonds in the insulin dimer interface. J. Biol. Chem. PMID: 21880708. [Epub ahead of print].
2. Bai, Y., Milne, J. S., Mayne, L., and Eng-lander, S. W. (1993). Primary structure effects on peptide group hydrogen exchange. Proteins 17, 75-86.
3. Bakaysa, D. L., Radziuk, J., Havel, H. A., Brader, M. L., Li, S., Dodd, S. W., Beals, J. M., Pekar, A. H., and Brems, D. N. (1996). Physicochemical basis for the rapid time-action of LysB28ProB29-insulin: dissociation of a protein-ligand complex. Protein Sci. 5, 2521-2531.
4. Baker, E. N., Blundell, T. L., Cutfield, J. F., Cutfield, S. M., Dodson, E. J., Dodson, G. G., Hodgkin, D. M., Hubbard, R. E., Isaacs, N. W., and Reynolds, C. D. (1988). The structure of 2Zn pig insulin crystals at 1.5Å resolution. Philos. Trans. R. Soc. Lond. B Biol. Sci. 319, 369-456.
5. Brange, J., Andersen, L., Laursen, E. D., Meyn, G., and Rasmussen, E. (1997). Toward understanding insulin fibrillation. J. Pharm. Sci. 86, 517-525.
6. Brange, J., Hansen, J. F., Langkjaer, L., Markussen, J., Ribel, U., and Sorensen,A. R. (1992a). Insulin ana-logues with improved absorption characteristics. Horm. Metab. Res. Suppl. 26, 125-130.
7. Brange, J., Havelund, S., and Hougaard, P. (1992b). Chemical stability of insulin. 2. Formation of higher molecular weight transformation products during storage of pharmaceutical preparations. Pharm. Res. 9, 727-734.
8. Brange, J., and Langkjoer, L. (1993). Insulin structure and stability. Pharm. Biotechnol. 5, 315-350.
9. Brange, J., Ribel, U., Hansen, J. F., Dod-son, G., Hansen, M. T., Havelund, S., Melberg, S. G., Norris, F., Norris, K., and Snel, L. (1988). Monomeric insulins obtained by protein engineering and their medical implications. Nature 333, 679-682.
10. Brange, J., Skelbaek-Pedersen, B., Langkjaer, L., Damgaard, U., Ege, H., Havelund, S., Heding, L. G., Jorgensen, H., Lykkeberg, J., Markussen, M., Pingel, M., and Rasmussen, E. (1987). Galenics of Insulin: The Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations. Berlin: Springer-Verlag.
11. Brunger, A. T. (1992). X-PLOR (Version 3.1) a System for X-Ray Crystallogra-phy and NMR. New Haven, CT: Yale University Press.
12. Bryant, C., Spencer, D. B., Miller, A., Bakaysa,D. L.,McCune,K. S.,Maple, S. R., Pekar, A. H., and Brems, D. N. (1993). Acid stabilization of insulin. Biochemistry 32, 8075-8082.
13. Campbell, R. K., Campbell, L. K., and White, J. R. (1996). Insulin lispro: its role in the treatment of dia-betes mellitus. Ann. Pharmacother. 30, 1263-1271.
14. Carroll, R. J., Hammer, R. E., Chan, S. J., Swift, H. H., Rubenstein, A. H., and Steiner, D. F. (1988). A mutant human proinsulin is secreted from islets of Langerhans in increased amounts via an unregulated path-way. Proc. Natl. Acad. Sci. U.S.A. 85, 8943-8947.
15. Chothia, C., Lesk, A. M., Dod-son, G. G., and Hodgkin, D. C. (1983). Transmission of conforma-tional change in insulin. Nature 302, 500-505.
16. Chu, Y. C., Zong, L., Burke, G. T., and Katsoyannis, P. G. (1992). The A14 position of insulin tolerates con-siderable structural alterations with modest effects on the biological behavior of the hormone. J. Protein Chem. 11, 571-577.
17. Ciszak, E., Beals, J. M., Frank, B. H., Baker, J. C., Carter, N. D., and Smith, G. D. (1995). Role of C-terminal B-chain residues in insulin assembly: the structure of hexam-eric LysB28ProB29-human insulin. Structure 3, 615-622.
18. Creighton, T. E. (1997). Protein Struc-ture: A Practical Approach. Oxford: IRL Press at Oxford University Press. De Meyts, P., and Whittaker, J. (2002). Structural biology of insulin and IGF1 receptors: implications for drug design. Nat. Rev. Drug Discov. 1, 769-783.
19. DeFelippis, M. R., Chance, R. E., and Frank, B. H. (2001). Insulin self-association and the relationship to pharmacokinetics and pharmacody-namics. Crit. Rev. Ther. Drug Carrier Syst. 18, 201-264.
20. Dodson, G., and Steiner, D. (1998). The role of assembly in insulin's biosyn-thesis. Curr. Opin. Struct. Biol. 8, 189-194.
21. Dodson, G. G., Dodson, E. J., Turken-burg, J. P., and Bing, X. (1993). Molecular recognition in insulin assembly. Biochem. Soc. Trans. 21, 609-614.
22. Englander, S. W., Sosnick, T. R., Eng-lander, J. J., and Mayne, L. (1996). Mechanisms and uses of hydrogen exchange. Curr. Opin. Struct. Biol. 6, 18-23.
23. Garg, S. K., Ellis, S. L., and Ulrich, H. (2005). Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin. Pharmacother. 6, 643-651.
24. Gerstein,H. C.,Miller,M. E.,Genuth,S., Ismail-Beigi,F.,Buse,J. B.,Goff,D. C. Jr.,Probstfield,J. L., Cushman,W. C., Ginsberg,H. N.,Bigger,J. T.,Grimm, R. H. Jr., Byington, R. P., Rosen-berg, Y. D., and Friedewald, W. T. (2011). Long-term effects of inten-sive glucose lowering on cardiovas-cular outcomes. N.Engl.J.Med.364, 818-828.
25. Guo, Z. Y., Zhang, Z., Jia, X. Y., Tang, Y. H., and Feng, Y. M. (2005). Muta-tional analysis of the absolutely con-served B8Gly: consequence on fold-ability and activity of insulin. Acta Biochim. Biophys. Sin. (Shanghai) 10, 673-679.
26. Hansen, B. F., Kurtzhals, P., Jensen, A. B., Dejgaard, A., and Russell-Jones, D. (2011). Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 54, 2226-2231.
27. Hartemann-Heurtier, A., Sachon, C., Masseboeuf, N., Corset, E., and Grimaldi, A. (2003). Functional intensified insulin therapy with short-acting insulin analog: effects on HbA1c and frequency of severe hypoglycemia. An observational cohort study. Diabetes Metab. 29, 53-57.
28. Hartman, I. (2008). Insulin analogs: impact on treatment, success, satis-faction,quality of life and adherence. Clin. Med. Res. 6, 54-67.
29. Havel, T. F., and Snow, M. E. (1991). A new method for building protein conformations from sequence align-ments with homologues of known structure. J. Mol. Biol. 217, 1-7.
30. Hober, S., Forsberg, G., Palm, G., Hartmanis, M., and Nilsson, B. (1992). Disulfide exchange folding of insulin-like growth factor I. Bio-chemistry 31, 1749-1756.
31. Hober, S., Hansson, A., Uhlen, M., and Nilsson, B. (1994). Fold-ing of insulin-like growth fac-tor I is thermodynamically con-trolled by insulin-like growth fac-tor binding protein. Biochemistry 33, 6758-6761.
32. Holleman, F., and Hoekstra, J. B. (1997). Insulin lispro. N.Engl.J.Med.337, 176-183.
33. Hu, S. Q., Burke, G. T., Schwartz, G. P., Ferderigos, N., Ross, J.B., and Kat-soyannis,P. G. (1993). Steric require-ments at position B12 for high bio-logical activity in insulin. Biochem-istry 32, 2631-2635.
34. Hua, Q. (2010). Insulin: a small protein with a long journey. Protein Cell 1, 537-551.
35. Hua, Q. X., Chu, Y. C., Jia, W., Phillips, N. B., Wang, R. Y., Katsoyannis, P. G., and Weiss, M. A. (2002a). Mech-anism of insulin chain combination. Asymmetric roles of A-chain alpha-helices in disulfide pairing. J. Biol. Chem. 277, 43443-43453.
36. Hua, Q. X., Jia,W., Frank, B. H., Phillips, N. B., and Weiss, M. A. (2002b). A protein caught in a kinetic trap: structures and stabilities of insulin disulfide isomers. Biochemistry 41, 14700-14715.
37. Hua, Q. X., Gozani, S. N., Chance, R. E., Hoffmann, J. A., Frank, B. H., and Weiss, M. A. (1995). Structure of a proteininakinetictrap.Nat. Struct. Biol. 2, 129-138.
38. Hua, Q. X., Hu, S. Q., Frank, B. H., Jia, W., Chu,Y. C.,Wang, S. H., Burke, G. T., Katsoyannis, P. G., and Weiss, M. A. (1996a). Mapping the functional surface of insulin by design: struc-ture and function of a novel A-chain analogue. J. Mol. Biol. 264, 390-403
39. Hua, Q. X., Narhi, L., Jia, W., Arakawa, T.,Rosenfeld,R.,Hawkins,N.,Miller, J. A., and Weiss, M. A. (1996b). Native and non-native structure in a protein-folding intermediate: spec-troscopic studies of partially reduced IGF-I and an engineered alanine model. J. Mol. Biol. 259, 297-313.
40. Hua, Q. X., Hu, S. Q., Jia, W., Chu, Y. C., Burke, G. T., Wang, S. H., Wang, R. Y., Katsoyannis, P. G., and Weiss, M. A. (1998). Mini-proinsulin and mini-IGF-I: homol-ogous protein sequences encoding non-homologous structures. J. Mol. Biol. 277, 103-118.
41. Hua, Q. X., Jia, W., Frank, B. H., and Weiss, M. A. (1993). Comparison of the dynamics of an engineered insulin monomer and dimer by acid-quenched amide proton exchange. Non-local stabilization of interchain hydrogen bonds by dimerization. J. Mol. Biol. 230, 387-394.
42. Hua, Q. X., Liu, M., Hu, S. Q., Jia, W., Arvan, P., and Weiss, M. A. (2006a). A conserved histidine in insulin is required for the foldability of human proinsulin. Structure and function of an AlaB5 analog. J. Biol. Chem. 281, 24889-24899.
43. Hua, Q. X., Mayer, J., Jia, W., Zhang, J., and Weiss, M. A. (2006b). The folding nucleus of the insulin super-family: a flexible peptide model fore-shadows the native state. J. Biol. Chem. 281, 28131-28142.
44. Hua, Q. X., Nakagawa, S. H., Hu, S. Q., Jia, W., Wang, S., and Weiss, M. A. (2006c). Toward the active con-formation of insulin. Stereospecific modulation of a structural switch in the B chain. J. Biol. Chem. 281, 24900-24909.
45. Hua, Q. X., Nakagawa, S. H., Jia, W., Hu, S. Q., Chu, Y. C., Katsoyan-nis, P. G., and Weiss, M. A. (2001). Hierarchical protein folding: asym-metric unfolding of an insulin ana-logue lacking the A7-B7 interchain disulfide bridge. Biochemistry 40, 12299-12311.
46. Hua, Q. X., Nakagawa, S. H., Jia, W., Huang, K., Phillips, N. B., Hu, S. Q., and Weiss, M. A. (2008). Design of an active ultrastable single-chain insulin analog: synthesis, structure, and therapeutic implications. J. Biol. Chem. 283, 14703-14716.
47. Hua, Q. X., Shoelson, S. E., Kochoyan, M., and Weiss, M. A. (1991). Recep-tor binding redefined by a structural switch in a mutant human insulin. Nature 354, 238-241.
48. Hua, Q. X., and Weiss, M. A. (1990). Toward the solution struc-ture of human insulin: sequential 2D 1H NMR assignment of a des-pentapeptide analogue and compar-ison with crystal structure. Biochem-istry 29, 10545-10555.
49. Hua, Q. X., and Weiss, M. A. (1991). Comparative 2D NMR studies of human insulin and des-pentapeptide insulin: sequential resonance assignment and impli-cations for protein dynamics and receptor recognition. Biochemistry 30, 5505-5515.
50. Huang,Y., Liang, Z., and Feng,Y. (2001). The relationship between the con-necting peptide of recombined sin-gle chain insulin and its biological function. Sci. China C Life Sci. 44, 593-600.
51. Ismail-Beigi, F., Moghissi, E., Tiktin, M., Hirsch, I. B., Inzucchi, S. E., and Genuth, S. (2011). Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clin-ical trials. Ann. Intern. Med. 154, 554-559.
52. Jia, X. Y., Guo, Z. Y., Wang, Y., Xu, Y., Duan, S. S., and Feng, Y. M. (2003). Peptide models of four pos-sible insulin folding intermediates with two disulfides. Protein Sci. 12, 2412-2419.
53. Kaarsholm, N. C., Norris, K., Jorgensen, R. J., Mikkelsen, J., Ludvigsen, S., Olsen, O. H., Sorensen, A. R., and Havelund, S. (1993). Engineering stability of the insulin monomer fold with application to structure-activity relationships. Biochemistry 32, 10773-10778.
54. Katsoyannis, P. G. (1966). Synthesis of insulin. Science 154, 1509-1514.
55. Kristensen, C., Kjeldsen, T., Wiberg, F. C., Schaffer, L., Hach, M., Havelund, S., Bass, J., Steiner, D. F., and Ander-sen, A. S. (1997). Alanine scanning mutagenesis of insulin. J. Biol. Chem. 272, 12978-12983.
56. Lefebvre, P., and Pierson, A. (2004). The global challenge of diabetes. World Hosp. Health Serv. 40, 37-40, 42.
57. Melki, V., Renard, E., Lassmann-Vague, V., Boivin, S., Guerci, B., Hanaire-Broutin, H., Bringer, J., Belicar, P., Jeandidier, N., Meyer, L., Blin, P., Augendre-Ferrante, B., and Tauber, J. P. (1998). Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 21, 977-982.
58. Milazzo, G., Sciacca, L., Papa, V., Goldfine, I. D., and Vigneri, R. (1997). ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial. Mol. Carcinog. 18, 19-25.
59. Miller, J. A., Narhi, L. O., Hua, Q. X., Rosenfeld, R., Arakawa, T., Rohde, M., Prestrelski, S., Lauren, S., Stoney, K. S., Tsai, L., and Weiss, M. A. (1993). Oxidative refold-ing of insulin-like growth factor 1 yields two products of similar ther-modynamic stability: a bifurcating protein-folding pathway. Biochem-istry 32, 5203-5213.
60. Milner, S. J., Carver, J. A., Ballard, F. J., and Francis, G. L. (1999). Prob-ing the disulfide folding pathway of insulin-like growth factor-I. Biotech-nol. Bioeng. 62, 693-703.
61. Nakagawa, S. H., Zhao, M., Hua, Q. X., Hu, S. Q., Wan, Z. L., Jia, W., and Weiss, M. A. (2005). Chi-ral mutagenesis of insulin. Fold-ability and function are inversely regulated by a stereospecific switch in the B chain. Biochemistry 44, 4984-4999.
62. Nathan, D. M., Cleary, P. A., Back-lund, J. Y., Genuth, S. M., Lachin, J. M., Orchard, T. J., Raskin, P., Zin-man, B., and DCCT/EDIC Study Research Group. (2005). Intensive diabetes treatment and cardiovas-cular disease in patients with type 1 diabetes. N. Engl. J. Med. 353, 2643-2653.
63. Nicollerat, J. A. (2000). Implications of the United Kingdom Prospective Diabetes Study (UKPDS) results on patient management. Diabetes Educ. 26(Suppl.), 8-10.
64. Osei, K. (2003). Global epidemic of type 2 diabetes: implications for develop-ing countries. Ethn. Dis. 13, S102-S106.
65. Qiao, Z. S., Guo, Z. Y., and Feng, Y. M. (2001). Putative disulfide-forming pathway of porcine insulin precur-sor during its refolding in vitro. Biochemistry 40, 2662-2668.
66. Qiao, Z. S., Min, C. Y., Hua, Q. X., Weiss, M. A., and Feng, Y. M. (2003). In vitro refolding of human proinsulin. Kinetic inter-mediates, putative disulfide-forming pathway, folding initiation site, and protential role of C-peptide in fold-ing process. J. Biol. Chem. 278, 17800-17809.
67. Rajpal,G.,Liu,M.,Zhang,Y.,and Arvan, P. (2009). Single-chain insulins as receptor agonists. Mol. Endocrinol. 23, 679-688.
68. Renner, R., Pfutzner,A., Trautmann, M., Harzer, O., Sauter, K., and Land-graf, R. (1999). Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a mul-ticenter trial. German Humalog-CSII Study Group. Diabetes Care 22, 784-788.
69. Riddle, M. C. (2010). Effects of inten-sive glucose lowering in the man-agement of patients with type 2 dia-betes mellitus in the Action to Con-trol Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 122, 844-846.
70. Roder, H. (1989). Structural charac-terization of protein folding inter-mediates by proton magnetic reso-nance and hydrogen exchange. Meth. Enzymol. 176, 446-473.
71. Roder, H., Wagner, G., and Wüthrich, K. (1985). Amide proton exchange in proteins by EX1 kinetics: studies of the basic pancreatic trypsin inhibitor at variable p2H and temperature. Biochemistry 24, 7396-7407.
72. Saltiel, A. R. (2001). New perspectives into the molecular pathogenesis and treatment of type-2 diabetes. Cell 104, 517-529.
73. Schwartz, G. P., Burke, G. T., and Katsoyannis, P. G. (1987). A superactive insulin: [B10-aspartic acid]insulin(human). Proc. Natl. Acad. Sci. U.S.A. 84, 6408-6411.
74. Selden, R. F., Skokiewicz, M. J., Howie, K. B., Russell, P. S., and Goodman, H. M. (1986). Regulation of human insulin gene expression in transgenic mice. Nature 321, 525-528.
75. Shoelson, S. E., Lu, Z. X., Parlautan, L., Lynch, C. S., and Weiss, M. A. (1992). Mutations at the dimer, hexamer, and receptor-binding, sur-faces of insulin independently affect insulin-insulin and insulin-receptor interactions. Biochemistry 31, 1757-1767.
76. Sosnick, T. R., Fang, X., and Shelton, V. M. (2000). Application of circu-lar dichroism to study RNA fold-ing transitions. Meth. Enzymol. 317, 393-409.
77. Steiner, D. F. (1967). Evidence for a pre-cursor in the biosynthesis of insulin. Trans. N. Y. Acad. Sci. 30, 60-68.
78. Stoy, J., Edghill, E. L., Flanagan, S. E., Ye, H., Paz, V. P., Pluzhnikov, A., Below, J. E., Hayes, M. G., Cox, N. J., Lipkind, G. M., Lipton, R. B., Gree-ley, S. A., Patch, A. M., Ellard, S., Steiner,D. F.,Hattersley,A. T.,Philip-son, L. H., and Bell, G. I. (2007). Insulin gene mutations as a cause of permanent neonatal diabetes. Proc. Natl. Acad. Sci. U.S.A. 104, 15040-15044.
79. Tang, J. G., and Tsou, C. L. (1990). The insulin A and B chains contain struc-tural information for the forma-tion of the native molecule. Studies with protein disulphide-isomerase. Biochem. J. 268, 429-435.
80. The Diabetes Control Group and Complications Trial Research Group. (1993). The effect of intensive treatment of diabetes on the development and progres-sion of long-term complications in insulin-dependent diabetes mellitus. N.Engl.J.Med.329, 977-986.
81. Tripathi, B. K., and Srivastava, A. K. (2006). Diabetes mellitus: compli-cations and therapeutics. Med. Sci. Monit. 12, RA130-RA147.
82. Wagner, G., and Wüthrich, K. (1986). Observation of internal motility of proteins by nuclear magnetic reso-nance in solution. Meth. Enzymol. 131, 307-326.
83. Wang, C. C., and Tsou, C. L. (1991). The insulin A and B chains contain suffi-cient structural information to form the native molecule. Trends Biochem. Sci. 16, 279-281.
84. Weiss, M. A. (2009). Proinsulin and the genetics of diabetes mellitus. J. Biol. Chem. 284, 19159-19163.
85. Weiss, M. A., Frank, B. H., Khait, I., Pekar, A., Heiney, R., Shoelson, S. E., and Neuringer, L. J. (1990). NMR and photo-CIDNP studies of human proinsulin and prohormone pro-cessing intermediates with applica-tion to endopeptidase recognition. Biochemistry 29, 8389-8401.
86. Weiss, M. A., Hua, Q. X., Lynch, C. S., Frank, B. H., and Shoel-son, S. E. (1991). Heteronuclear 2D NMR studies of an engineered insulin monomer: assignment and characterization of the receptor-binding surface by selective 2H and 13C labeling with application to protein design. Biochemistry 30, 7373-7389.
87. Wüthrich, K. (1986). NMR of Proteins and Nucleic Acids.NewYork,NY: John Wiley & Sons.
88. Wüthrich, K., and Wagner, G. (1979). Nuclear magnetic resonance of labile protons in the basic pancreatic trypsin inhibitor. J. Mol. Biol. 130, 1-18.
89. Yang, Y., Hua, Q. X., Liu, J., Shimizu, E. H., Choquette, M. H., Mackin, R. B., and Weiss, M. A. (2010a). Solution structure of proinsulin: connecting domain flexibility and pro-hormone processing. J. Biol. Chem. 285, 7847-7851.
90. Yang, Y., Petkova, A., Huang, K., Xu, B., Hua, Q. X., Ye, I. J., Chu, Y. C., Hu, S. Q., Phillips, N. B., Whittaker, J., Ismail-Beigi, F., Mackin, R. B., Katsoyannis, P. G., Tycko, R., and Weiss, M. A. (2010b). An Achilles' Heel in an amyloidogenic protein and its repair. Insulin dynamics, misfolding, and therapeutic design. J. Biol. Chem. 285, 10806-10821.
91. Zinman, B., Tildesley, H., Chiasson, J. L., Tsui, E., and Strack, T. (1997). Insulin lispro in CSII: results of a double-blind crossover study. Dia-betes 46, 440-443